Your experience on this site will be improved by allowing cookies.
N E W S
New video - Ruxolitinib cream, a first treatment approved in Europe for vitiligo. Intervention recorded in Paris on June 3, 2023, during the Annual Meetings of Vitiligo organized by the French Association of Vitiligo.
2 new studies start in the treatment of vitiligo Study for the treatment of external genitalia. Study for classically resistant areas (wrist, back of hands, elbows and knees). More information in the section “Clinical trials in progress" or "Upcoming trials” or by calling 04 92 03 62 25
Last oportunities to participate to the ERASE vitiligo study patients between 18 to 40 with a vitiligo for last than 6 months. Please contact Mr Houis Adrien ( houis.a@chu-nice.fr )
After the FDA approval, ruxolitinib cream just received the EMA approval for treating vitiligo for patients above 12
More information by contacting us +33 4 92 03 62 25
Trials in progress
Assessment of Circulating Functional Mitochondrias in Vitiligo Patients.
ClinicalTrial Identifier : NCT05525741
Status : Trial in progress
Recruitment : Open
Study PREVENT Vitiligo : combination treatment of epidermal suspension transplantation and topical ruxolitinib for hard-to-treat areas.
ClinicalTrial Identifier :
Status : Trial in progress
Recruitment : Open
ERASE VITILIGO Early Repigmentation Approach for Stopping the Evolution of VITILIGO Prospective Multicentric Interventional Study With Blinded Evaluation (ERASE).
ClinicalTrial Identifier : NCT04843059
Status : Trial in progress
Recruitment : Open
Study of the mode of action of ruxolitinib cream in vitiligo.
ClinicalTrial Identifier : NCT04896385
Status : Trial in progress
Recruitment : Closed
Etude BARVIT. Baracitinib par voie orale dans les vitiligos actifs.
ClinicalTrial Identifier : NCT04822584
Status : Trial in progress
Recruitment : Closed
Upadacitinib par voie orale dans les vitiligos étendus.
ClinicalTrial Identifier : NCT04927975
Status : Trial in progress
Recruitment : Closed